BioCentury
ARTICLE | Clinical News

CellSearch Circulating Tumor Cell Kit: Clinical trial data

August 12, 2013 7:00 AM UTC

A double-blind, Chinese trial analyzing blood samples from 294 evaluable patients with metastatic breast cancer showed that detection of <5 CTCs at baseline as measured by Veridex LLC's CellSearch Circulating Tumor Cell Kit predicted significantly longer median PFS (9 vs. 6.7 months, p<0.001) and OS (>24.6 vs. 13.2 months, p<0.001) compared to patients with >=5 CTCs at baseline. Similar results were observed for CTC counts at the first follow-up visit for both PFS (p=0.049) and OS (p<0.001). The trial enrolled 300 metastatic breast cancer patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 who were starting a new line of systemic therapy, including any form of endocrine manipulation, cytotoxic chemotherapy or immunotherapy, alone or in combination. Data were published in Annals of Oncology. ...